Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$7.08 USD
-0.06 (-0.84%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $7.07 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AUPH 7.08 -0.06(-0.84%)
Will AUPH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't?
Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
Other News for AUPH
Aurinia Pharmaceuticals: This Recovery Can Continue
Aurinia Pharmaceuticals shares gain as co reports Board restructuring
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
Aurinia Announces Board Restructuring
Significant Acquisition by TANG CAPITAL MANAGEMENT LLC in Aurinia Pharmaceuticals Inc